Zepbound shows higher weight loss results compared to Wegovy in recent studies.
Eli Lilly’s obesity drug Zepbound has outperformed Novo Nordisk’s Wegovy in a head-to-head clinical trial. The study shows Zepbound led to nearly 50% more weight loss compared to Wegovy. Participants using Zepbound lost an average of 50 pounds over 72 weeks, while those on Wegovy lost about 33 pounds. Despite mild side effects, Zepbound also demonstrated significant health improvements, highlighting its potential as a leading weight loss therapy amidst growing demand for GLP-1 medications.
In an exciting turn of events in the world of weight loss medications, Eli Lilly’s latest obesity drug, Zepbound (tirzepatide), has taken the crown from Novo Nordisk’s popular solution, Wegovy (semaglutide), in a head-to-head clinical trial. The study, which was backed by Eli Lilly and published in the esteemed New England Journal of Medicine, shows that those taking Zepbound lost nearly 50% more weight compared to their Wegovy counterparts.
The clinical trial involved a total of 751 adults in the United States, all of whom were either overweight or had obesity. The participants also had at least one weight-related health issue but did not suffer from diabetes. Throughout the span of 72 weeks, individuals taking Zepbound experienced significant results, shedding an average of 50 pounds (22.8 kilograms). Comparatively, those on Wegovy lost about 33 pounds (15 kilograms) during the same timeframe.
The results showed that folks on Zepbound lost approximately 20% of their body weight on average, whereas Wegovy users lost nearly 14%. Participants in the Zepbound group also reduced their waist circumference by around 7 inches (17.8 centimeters), compared to a loss of about 5 inches (12.7 centimeters) for those using Wegovy. Impressive, right?
Breaking it down further, around 32% of participants on Zepbound achieved a remarkable weight loss of at least 25% of their body weight, while only about 16% of those on Wegovy reached that milestone. Interestingly, weight loss was seen to be about 6% lower in men compared to women across both groups, a pattern that researchers will surely be watching.
Alongside the remarkable weight loss, participants in the study noticed improvements in key health markers including blood pressure, blood fat, and blood sugar levels. Sounds like a double win for those trying to get healthier!
As with any medication, side effects were reported. Over three-quarters of participants experienced at least one side effect, mostly mild to moderate gastrointestinal issues such as nausea and diarrhea. Notably, 6% of Zepbound users discontinued the drug due to adverse events, outmatching the 8% dropout rate for Wegovy.
Both Zepbound and Wegovy have gained momentum, with a recent survey showing that 1 in 8 U.S. adults are currently using GLP-1 medications. Zepbound also made headlines last year with a whopping $4.9 billion in global sales, while Wegovy outshone it with nearly $8.8 billion. Clearly, many are turning to these medications for help with weight loss.
However, not all news is rosy. Both medications have faced scrutiny over access and affordability, which are barriers to wider use amongst the population. Thankfully, recent updates indicate both drugs have been removed from the FDA’s list of drug shortages, potentially paving the way for more individuals to gain access.
In a notable market update, CVS Health has announced that starting July 1, Wegovy will officially become the preferred weight-loss drug in its standard formulary, although it won’t include Zepbound. As the battle of the weight-loss medications continues, it’s clear that options are expanding for those eager to seize control of their health.
The weight loss journey can sometimes feel daunting, but with advancements like Zepbound and Wegovy, there’s hope on the horizon. As these options gain popularity, they are generating conversations across the nation about the possibilities for better health and wellness.
News Summary Recent data from the New York State Department of Health reveals a significant…
News Summary Almaz Med Supply, a company in Queens, is facing scrutiny for allegedly billing…
News Summary Dime Community Bank successfully hosted its 10th annual $10K Small Business Challenge in…
News Summary Billionaire investor Bill Ackman has announced his intention to back a centrist candidate…
News Summary New York City is experiencing increased real estate activity with new restaurant leases,…
News Summary The New York Times Company has declared a quarterly dividend of $0.18 per…